Detecting brain metastasis in colorectal cancer patients using MRI
Dépistage Des métastases cérébrales Par IRM Chez Les Patients Avec un adénocarcinome Colorectal métastatique
This study tests if regular MRI scans can help find brain tumors early in colorectal cancer patients who already have cancer spread to other parts of their body.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Poitiers University Hospital Academic / other |
| Locations | 4 sites (Amiens and 3 other locations) |
| Trial ID | NCT03694938 on ClinicalTrials.gov |
What this trial studies
This study aims to prospectively assess the incidence of brain metastases in patients with metastatic colorectal cancer through systematic annual screening using magnetic resonance imaging (MRI). By identifying brain metastases early, the study seeks to improve patient management and treatment outcomes. Participants will be patients with confirmed colorectal adenocarcinoma who have been diagnosed with metastases within the last six months and are indicated for oncologic treatment. The study will exclude patients with contraindications for MRI and those with recent diagnoses of other cancers.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with histologically confirmed metastatic colorectal adenocarcinoma diagnosed within the last six months.
Not a fit: Patients with contraindications for MRI or those diagnosed with other cancers in the last three years may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of brain metastases in colorectal cancer patients, potentially improving treatment options and outcomes.
How similar studies have performed: While the approach of using MRI for screening in this context is established, the specific focus on annual screening for brain metastases in this patient population is less common and may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with histologically proven colorectal adenocarcinoma * Metastases from colorectal cancer diagnosed since less than 6 months * Indication of an oncologic treatment Exclusion Criteria: * Patient with contraindication for MRI * Diagnosis of cancer other than colorectal cancer in the last three years, except in situ cancers, basal-cell skin cancer or squamous-cell skin cancer, and other cancer with low risk of brain dissemination according to the investigator * Pregnant or breastfeeding women, women of childbearing potential without effective contraception
Where this trial is running
Amiens and 3 other locations
- C.H.U. d'Amiens — Amiens, France (Terminated)
- Hôpital Privé Jean Mermoz — Lyon, France (Recruiting)
- C.H.U. de Poitiers — Poitiers, France (Recruiting)
- C.H.U. de Tours — Tours, France (Recruiting)
Study contacts
- Study coordinator: David TOUGERON, MD, PhD
- Email: david.tougeron@chu-poitiers.fr
- Phone: 0549443751
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.